Daxor (DXR) Stock Rating Upgraded by TheStreet

Daxor (NYSEAMERICAN:DXR) was upgraded by equities research analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued on Thursday.

NYSEAMERICAN DXR traded up $1.78 during mid-day trading on Thursday, reaching $13.00. 102,104 shares of the company’s stock traded hands, compared to its average volume of 73,750. Daxor has a 1-year low of $3.40 and a 1-year high of $21.66.

About Daxor

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply